GBT Annual Total Expenses
$482.44 M
+$114.48 M+31.11%
31 December 2021
Summary:
As of February 5, 2025, GBT annual total expenses is $482.44 million, with the most recent change of +$114.48 million (+31.11%) on December 31, 2021. During the last 3 years, it has risen by +$299.70 million (+164.00%).GBT Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GBT Quarterly Total Expenses
$147.28 M
+$18.86 M+14.68%
30 June 2022
Summary:
As of February 5, 2025, GBT quarterly total expenses is $147.28 million, with the most recent change of +$18.86 million (+14.68%) on June 30, 2022. Over the past year, it has increased by +$33.65 million (+29.62%).GBT Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GBT Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +31.1% | +29.6% |
| 3 y3 years | +164.0% | +142.2% |
| 5 y5 years | +304.6% | +502.9% |
GBT Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time | at high | at high |
Global Blood Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| June 2022 | - | $147.28 M(+14.7%) |
| Mar 2022 | - | $128.42 M(-7.7%) |
| Dec 2021 | $482.44 M(+31.1%) | $139.06 M(+16.5%) |
| Sept 2021 | - | $119.35 M(+5.0%) |
| June 2021 | - | $113.63 M(+2.9%) |
| Mar 2021 | - | $110.41 M(+8.6%) |
| Dec 2020 | $367.96 M(+26.1%) | $101.65 M(+6.8%) |
| Sept 2020 | - | $95.20 M(+14.0%) |
| June 2020 | - | $83.54 M(-4.6%) |
| Mar 2020 | - | $87.57 M(-20.1%) |
| Dec 2019 | $291.69 M(+59.6%) | $109.63 M(+59.5%) |
| Sept 2019 | - | $68.74 M(+13.1%) |
| June 2019 | - | $60.80 M(+15.8%) |
| Mar 2019 | - | $52.52 M(+0.8%) |
| Dec 2018 | $182.74 M | $52.08 M(+14.5%) |
| Sept 2018 | - | $45.48 M(+7.0%) |
| June 2018 | - | $42.49 M(-0.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $42.70 M(+1.9%) |
| Dec 2017 | $119.25 M(+43.4%) | $41.91 M(+43.6%) |
| Sept 2017 | - | $29.18 M(+19.4%) |
| June 2017 | - | $24.43 M(+3.0%) |
| Mar 2017 | - | $23.72 M(-13.6%) |
| Dec 2016 | $83.13 M(+79.2%) | $27.46 M(+29.9%) |
| Sept 2016 | - | $21.14 M(+18.7%) |
| June 2016 | - | $17.81 M(+6.5%) |
| Mar 2016 | - | $16.72 M(+7.2%) |
| Dec 2015 | $46.39 M(+126.2%) | $15.60 M(+5.6%) |
| Sept 2015 | - | $14.78 M(+71.8%) |
| June 2015 | - | $8.60 M(+15.9%) |
| Mar 2015 | - | $7.42 M(+39.6%) |
| Dec 2014 | $20.51 M(+31.0%) | $5.31 M(+2.2%) |
| Sept 2014 | - | $5.20 M(+1.4%) |
| June 2014 | - | $5.13 M(+5.3%) |
| Mar 2014 | - | $4.87 M |
| Dec 2013 | $15.66 M | - |
FAQ
- What is Global Blood Therapeutics annual total expenses?
- What is the all time high annual total expenses for Global Blood Therapeutics?
- What is Global Blood Therapeutics annual total expenses year-on-year change?
- What is Global Blood Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Global Blood Therapeutics?
- What is Global Blood Therapeutics quarterly total expenses year-on-year change?
What is Global Blood Therapeutics annual total expenses?
The current annual total expenses of GBT is $482.44 M
What is the all time high annual total expenses for Global Blood Therapeutics?
Global Blood Therapeutics all-time high annual total expenses is $482.44 M
What is Global Blood Therapeutics annual total expenses year-on-year change?
Over the past year, GBT annual total expenses has changed by +$114.48 M (+31.11%)
What is Global Blood Therapeutics quarterly total expenses?
The current quarterly total expenses of GBT is $147.28 M
What is the all time high quarterly total expenses for Global Blood Therapeutics?
Global Blood Therapeutics all-time high quarterly total expenses is $147.28 M
What is Global Blood Therapeutics quarterly total expenses year-on-year change?
Over the past year, GBT quarterly total expenses has changed by +$33.65 M (+29.62%)